NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BHVN

Biohaven Ltd

Jun 30 • 04:00PM ET

14.11

Dollar change +0.02
Percentage change 0.14	%

Healthcare • Biotechnology • USA • NYSE

Peers: VRTX AMGN REGN GILD BMRN NBIX ALNY INCY SRPT EXEL

| Held by: VTI IWM VB XBI VXF VBR IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-9.37	Insider Own	12.68%	Shs Outstand	102.10M	Perf Week	-2.42%
Market Cap	1.44B	Forward P/E	-	EPS next Y	-6.36	Insider Trans	0.25%	Shs Float	89.17M	Perf Month	-4.27%
Enterprise Value	1.15B	PEG	-	EPS next Q	-1.90	Inst Own	88.79%	Short Float	12.20%	Perf Quarter	-48.97%
Income	-888.60M	P/S	-	EPS this Y	16.89%	Inst Trans	-1.70%	Short Ratio	4.85	Perf Half Y	-60.53%
Sales	0.00M	P/B	5.55	EPS next Y	17.54%	ROA	-202.53%	Short Interest	10.88M	Perf YTD	-62.22%
Book/sh	2.54	P/C	4.45	EPS next 5Y	17.95%	ROE	-316.82%	52W High	55.70 -74.67%	Perf Year	-59.71%
Cash/sh	3.17	P/FCF	-	EPS past 3/5Y	-40.84% -49.78%	ROIC	-306.10%	52W Low	13.87 1.73%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.80% 5.41%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-37.00%	Oper. Margin	-	ATR (14)	0.95	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.90	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	2.33	EPS Q/Q	1.15%	SMA20	-7.96%	Beta	3.50	Target Price	54.21
Payout	-	Debt/Eq	0.14	Sales Q/Q	-	SMA50	-19.46%	Rel Volume	0.76	Prev Close	14.09
Employees	256	LT Debt/Eq	0.12	Earnings	May 12 AMC	SMA200	-58.54%	Avg Volume	2.24M	Price	14.11
IPO	May 04, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-27.62% -	Trades		Volume	1,697,452	Change	0.14%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$21
Feb-11-25	Initiated	Deutsche Bank	Buy	$65
Sep-16-24	Initiated	Jefferies	Buy	$57
Sep-04-24	Initiated	Bernstein	Outperform	$55
Jul-24-24	Initiated	Morgan Stanley	Overweight	$58
Feb-16-24	Initiated	RBC Capital Mkts	Outperform	$62
Feb-06-24	Initiated	UBS	Buy	$59
Dec-22-23	Initiated	H.C. Wainwright	Buy	$50
Dec-08-23	Initiated	Robert W. Baird	Outperform	$58
Jan-24-23	Initiated	SVB Securities	Outperform	$24
Jan-04-23	Initiated	JP Morgan	Overweight	$23
Dec-02-22	Initiated	BTIG Research	Buy	$24
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$158 → $27
Oct-12-22	Initiated	Piper Sandler	Overweight	$23
Aug-19-22	Downgrade	Piper Sandler	Overweight → Neutral	$149
Aug-08-22	Downgrade	Wedbush	Outperform → Neutral	$148.50
May-11-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$150
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight	$107 → $145
Aug-10-21	Downgrade	UBS	Buy → Neutral	$108 → $109
Aug-03-21	Reiterated	Canaccord Genuity	Buy	$101 → $150

Show Previous Ratings

Jun-10-25 02:00PM	Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development (GlobeNewswire)
May-29-25 07:01AM	Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor (PR Newswire)
12:16AM	Biohaven Ltd. (BHVN)'s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy (Insider Monkey)
May-28-25 03:00PM	Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN) (PR Newswire)
07:30AM	Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors (PR Newswire)
06:03PM	Loading…
May-15-25 06:03PM	Why Biohaven Stock Dove by Nearly 20% on Thursday (Motley Fool) -19.53%
02:06PM	Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug (Investor's Business Daily)
01:22PM	Why Is Biohaven Stock Falling On Thursday? (Benzinga)
May-14-25 06:43PM	FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia (PR Newswire)
May-12-25 04:05PM	Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -5.11%
May-09-25 08:49AM	Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts (Insider Monkey)
May-05-25 08:00AM	Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict (Seeking Alpha)
Apr-28-25 01:16PM	Why BioHaven Stock Is Soaring Today (Motley Fool) +9.58%
07:30AM	Biohaven Announces Investment up to $600 Million by Oberland Capital (PR Newswire)
Apr-26-25 12:10PM	Biohaven share price undervaluing pipeline potential, says RBC Capital (TipRanks)
05:10PM	Loading…
Apr-25-25 05:10PM	Why Biohaven Stock Plummeted by More Than 15% Today (Motley Fool) -15.21% +9.58%
Apr-23-25 06:12PM	Jim Cramer Says Biohaven (BHVN) Is "Too Cheap" and He's a Buyer at $21 (Insider Monkey) +9.24%
01:02PM	Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-18-25 03:36AM	Xenon- A Later Stage Story (Seeking Alpha)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha) +9.05%
Apr-05-25 09:00AM	Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
Apr-03-25 09:30AM	Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March (Motley Fool) -13.22%
Apr-01-25 11:55AM	American Century Companies boosts stake in Biohaven, ETF Daily News says (TipRanks) -5.99%
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-09-25 04:37PM	Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 (Insider Monkey)
Mar-07-25 10:31AM	Biohaven price target lowered to $63 from $69 at Morgan Stanley (TipRanks)
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Mar-03-25 07:31AM	Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 (PR Newswire) -13.77%
07:30AM	Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-11-25 06:42PM	Why Biohaven Stock Triumphed on Tuesday (Motley Fool) +11.19%
04:11PM	Loading…
04:11PM	Biohaven Just Hurdled An FDA Setback And Its Moving Lines (Investor's Business Daily)
01:29PM	Why Biohaven (BHVN) Stock Is Rallying Today (Insider Monkey)
07:30AM	Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia (PR Newswire)
Jan-24-25 05:48PM	Pfizer to Pay $60 Million in Kickback, False Claims Settlement (The Wall Street Journal)
Jan-13-25 11:15AM	Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy (PR Newswire)
Jan-12-25 08:04PM	Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs (GlobeNewswire)
Jan-07-25 05:54PM	Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-17-24 02:23PM	Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval (Benzinga) -5.60%
06:06AM	Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-16-24 07:30AM	Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates (PR Newswire) +7.72%
Dec-06-24 07:30AM	Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting (PR Newswire)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga)
07:30AM	Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity (PR Newswire)
Nov-12-24 04:05PM	Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +10.75%
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
Oct-02-24 04:05PM	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Oct-01-24 06:00AM	Biohaven Announces Pricing of $250 Million Public Offering of Common Shares (PR Newswire)
Sep-30-24 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire)
07:30AM	Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine (PR Newswire)
Sep-23-24 07:30AM	Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) (PR Newswire) +13.74%
Sep-20-24 07:09PM	Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia (PR Newswire)
Aug-08-24 08:21PM	Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? (Insider Monkey) +5.93% +6.25%
04:05PM	Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
Jul-01-24 07:00AM	Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors (GlobeNewswire)
Jun-28-24 10:00AM	The 3 Smartest Healthcare Stocks to Buy With $1K Right Now (InvestorPlace)
May-29-24 07:30AM	Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day (PR Newswire) -12.57%
07:15AM	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors (PR Newswire)
May-15-24 11:00AM	Director Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
May-14-24 09:35AM	Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround (Zacks) +10.24%
May-13-24 09:35AM	Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround (Zacks) -5.35%
May-09-24 11:54PM	BHVN Stock Earnings: Biohaven Misses EPS for Q1 2024 (InvestorPlace) -13.71%
04:05PM	Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
May-01-24 02:38PM	Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar (InvestorPlace)
Apr-26-24 06:00AM	3 Biotech Stocks to Buy on the Dip: April 2024 (InvestorPlace)
Apr-25-24 11:00AM	Director Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
Apr-23-24 11:00AM	Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
Apr-22-24 04:05PM	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Apr-18-24 06:00AM	Biohaven Announces Pricing of $230 Million Public Offering of Common Shares (PR Newswire)
Apr-17-24 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire)
Apr-13-24 09:00AM	Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates (PR Newswire)
Apr-03-24 10:03PM	LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside? (TipRanks)
Feb-29-24 04:05PM	Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments (PR Newswire)
Jan-25-24 05:31PM	Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs (InvestorPlace)
Jan-22-24 07:00AM	Obesity Drugs Lead to Muscle LossPharma Companies Want to Fix That (The Wall Street Journal) +9.24%
Jan-08-24 07:30AM	Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology (PR Newswire) +10.50%
Jan-02-24 07:00AM	Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-31-23 03:01AM	Director Irina Antonijevic Sells 11,000 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
Dec-01-23 04:30PM	Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting (PR Newswire)
Nov-16-23 09:40AM	Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-14-23 09:15PM	Biohaven Ltd (BHVN) Reports Q3 2023 Financial Results: Advances in Clinical Programs and Strong ... (GuruFocus.com)
04:05PM	Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments (PR Newswire)
Nov-06-23 08:50AM	Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -6.39%
Oct-31-23 09:40AM	Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year? (Zacks)
Oct-19-23 08:50AM	Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going (Zacks)
Oct-16-23 07:00AM	Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek (PR Newswire)
Oct-06-23 01:01PM	Insider Buying: CFO Matthew Buten Acquires 22,727 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
Oct-05-23 04:05PM	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) +5.32%
Oct-03-23 08:50AM	Here's What Could Help Biohaven Ltd. (BHVN) Maintain Its Recent Price Strength (Zacks)
Oct-02-23 11:56PM	Biohaven Announces Pricing of $225 Million Public Offering of Common Shares (PR Newswire) -7.46%
04:36PM	BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES (PR Newswire)
Sep-29-23 10:00AM	Small Biotech Stocks Haven't Shined of Late, but I Think These 3 Could Be Stars (TheStreet.com)
10:00AM	3 Small Biotech Stocks That Could Be Stars (TheStreet.com)
Sep-28-23 07:53AM	Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug (Zacks) +10.54%
Sep-27-23 04:09PM	Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33% (Investor's Business Daily) +33.31%
12:25PM	Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% (Investor's Business Daily)
12:00PM	Why Biohaven Stock Is Skyrocketing Today (Motley Fool)
Sep-14-23 07:00AM	Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy (PR Newswire)
Sep-05-23 07:00AM	Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies (PR Newswire) -6.18%
Aug-09-23 06:01AM	Independent Director of Biohaven Picks Up 1.8% More Stock (Simply Wall St.)

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHILDS JOHN W	Director	Mar 04 '25	Buy	30.47	32,700	996,238	2,320,571	Mar 05 07:01 AM
Car Bruce	Chief Scientific Officer	Jan 05 '25	Option Exercise	0.00	4,750	0	7,133	Jan 07 08:51 PM
Gentile Kimberly	SVP, Clinical Operations	Jan 05 '25	Option Exercise	0.00	3,750	0	99,719	Jan 07 08:50 PM
Clark George C.	VP, Chief Accounting Officer	Jan 05 '25	Option Exercise	0.00	2,500	0	66,168	Jan 07 08:50 PM
Buten Matthew	Chief Financial Officer	Jan 05 '25	Option Exercise	0.00	4,250	0	196,013	Jan 07 08:49 PM
Coric Vlad	Chief Executive Officer	Jan 05 '25	Option Exercise	0.00	14,250	0	1,803,409	Jan 07 08:48 PM
CHILDS JOHN W	Director	Dec 30 '24	Buy	35.94	29,000	1,042,393	2,368,741	Dec 31 07:00 AM
CHILDS JOHN W	Director	Oct 02 '24	Buy	47.50	21,052	999,970	21,052	Oct 03 07:01 AM
Coric Vlad	Chief Executive Officer	Oct 02 '24	Buy	47.50	21,052	999,970	861,942	Oct 03 07:00 AM
Bailey Gregory	Director	Sep 24 '24	Buy	44.19	5,000	220,966	1,620,071	Sep 25 07:30 AM
CHILDS JOHN W	Director	Jul 18 '24	Buy	35.67	28,400	1,012,983	2,339,741	Jul 19 08:56 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BHVN

Biohaven Ltd

Upgrade your FINVIZ experience